Levee Medical is a medtech company developing the Voro Urologic Scaffold to improve continence outcomes after prostate cancer surgery, and this weekly summary reviews its latest funding and clinical trial progress. The company advanced both its pivotal ARID II trial and its financing position over the past week.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Levee Medical reported an oversubscribed funding round exceeding $12 million, completed ahead of its original schedule. The capital is intended to extend the firm’s cash runway and support progress toward a Premarket Approval submission for the Voro scaffold following completion of ARID II enrollment.
Management indicated that strong investor participation and early clinical adoption underscore confidence in the device’s potential and the regulatory strategy. The new funding is expected to back continued enrollment of leading surgeons, operational acceleration, and disciplined execution of the PMA pathway.
The ARID II IDE pivotal trial is a multicenter randomized study in men undergoing robotic-assisted radical prostatectomy, designed to evaluate the safety and effectiveness of the Voro scaffold. The trial focuses on both early and long-term continence outcomes, reflecting an emphasis on quality-of-life measures in post-prostatectomy care.
According to company communications, 40 surgeons are now participating in ARID II under the leadership of principal investigator Dr. Scott Eggener of UCLA. Clinical leaders highlighted efforts to standardize an evidence-based, reproducible implant technique, which may support consistent outcomes and eventual adoption if results are favorable.
During the week, Levee Medical also announced that UChicago Medicine and Dr. Abhinav Sidana enrolled their first patient in ARID II, becoming the 15th site to do so. This additional academic center adds to the geographic and institutional diversity of the pivotal study and may enhance the robustness and credibility of the final dataset.
The company’s updates suggest steady progress in site activation and patient enrollment, though no specific timelines, enrollment targets, or interim efficacy data were disclosed. As a result, visibility into time to potential approval and commercialization remains limited despite the strengthened balance sheet.
Collectively, the oversubscribed financing and continued ARID II enrollment appear to reinforce Levee Medical’s position as it advances its first product candidate toward key regulatory milestones. Overall, the week marked meaningful, if incremental, momentum on both the clinical and capital fronts for the company.